AI Recognized as Core Business Capability in Pharmaceuticals at CPHI Frankfurt Event

At the CPHI Frankfurt event, Bruno Fabre emphasized the growing role of artificial intelligence (AI) in the pharmaceutical industry, urging companies to recognize AI as a core business capability rather than treating it as an auxiliary tool. Fabre highlighted that AI is not merely a resource for enhancing operations but increasingly functions as a competitor within the sector.

Fabre’s remarks focused on how AI is transforming traditional business models in pharmaceuticals. He stressed that organizations need to adapt their strategies to integrate AI at the foundational level of their operations. By doing so, companies can better position themselves in an industry where AI-driven solutions are advancing rapidly and reshaping processes such as drug discovery, clinical trials, and supply chain management.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: October 30, 2025

Related posts:

Beyond instruments: streamlining process technology implementation in biopharmaceutical manufacturing Cell Therapy Involves Administering Living Human Cells to Treat Cancer and Genetic Disorders Study Links Cholesterol Metabolism Disruptions to Age-Related Macular Degeneration Progression Study Finds Racial Disparities in Anticoagulant Prescriptions for Atrial Fibrillation and Flutter Patients

Author

GOAI